Mark R. Green, MD | Authors

8940 DARROW RD

Articles

Managing Non-Small-Cell Lung Cancer: Further Considerations

November 01, 2006

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Before 1980, radiotherapy was considered the only real recourse in advanced disease. In 1995, a landmark meta-analysis of trials conducted in the 1980s and early 1990s demonstrated a survival benefit with platinum-based chemotherapy. Newer chemotherapy agents and improved supportive care measures have allowed more patients to benefit from chemotherapy with reduced toxicity. Concurrent platinum-based chemotherapy and radiotherapy has improved the survival in stage III disease, and recently chemotherapy has also demonstrated improved survival in resected early-stage disease. The majority of patients still present with advanced unresec disease for whom the prognosis remains poor, but for key subpopulations the outlook has improved markedly since the emergence of targeted therapies directed against the epidermal growth factor receptor and vascular endothelial growth factor receptor pathways. Patient selection and the incorporation of targeted therapies with cytotoxic chemotherapy are the focus of many ongoing studies, and there is an abundance of new agents undergoing clinical trials. Together, these developments have moved us away from the nihilism of 20 years ago into an era of unprecedented optimism in taking on the many remaining challenges of managing NSCLC in the 21st century.

Commentary (Green): First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

November 01, 2005

In their excellent review of firstlinechemotherapy for patientswith advanced non–small-cell lungcancer (NSCLC), Laskin and Sandlerare clear, direct, and positive. Chemotherapyworks in stage IV disease:

Irinotecan and Gemcitabine in Patients With Solid Tumors: Phase I Trial

May 02, 2002

Using a day 1 and 8, every-3-week schedule, our purpose was to determine the maximum tolerated dose of irinotecan (CPT-11, Camptosar) that can be administered immediately after gemcitabine (Gemzar) at a dose of 1,000 mg/m² IV. In this phase I trial, the maximum tolerated dose was defined as the dose level immediately below the level in which two of the first three patients in any cohort, or at least two of six patients in any expanded cohort, experienced dose-limiting toxicity. Dose-limiting toxicity pertained only to toxicity during the first cycle of treatment. Escalation of irinotecan was planned in groups of three patients, with three additional patients added at the first indication of dose-limiting toxicity. A total of 19 patients have been enrolled.

Irinotecan/Gemcitabine Combination Chemotherapy in Pancreatic Cancer

March 02, 2001

Gemcitabine (Gemzar) and irinotecan (CPT-11, Camptosar) are active cytotoxic drugs against pancreatic cancer. Preclinical data evaluating the combination of gemcitabine and irinotecan suggest dose-dependent synergistic

Docetaxel Followed by Gemcitabine and Irinotecan in Solid Tumors

January 01, 2001

Docetaxel (Taxotere), gemcitabine (Gemzar), and irinotecan (Camptosar, CPT-11) are active single agents in a variety of solid tumors. In combination, synergism may be schedule dependent. Preclinical studies suggested

Irinotecan in the Management of Patients With Pancreatic Cancer

December 03, 2000

Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan ( Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with

Advances in the Management of Lung Cancer

July 01, 2000

In October 1999, 40 leading experts from Europe, the United States, and the Far East met in St. Julians, Malta, to discuss recent progress in the management of lung cancer. Emphasis was placed on novel treatment strategies for non–small-cell

Advances in Treatment of Inoperable NSCLC: Gemcitabine Doublets-A Promising Alternative

July 01, 2000

Gemcitabine (Gemzar) was originally approved for use in combination with cisplatin (Platinol) for the treatment of advanced non–small-cell lung cancer (NSCLC). Research began to focus on combining gemcitabine with newer